Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. - Wikidata - wikimedia - TriplyDB

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

http://www.wikidata.org/entity/Q33366562

about

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer Systemic Chemotherapy in Advanced Pancreatic Cancer Systemic treatment for inoperable pancreatic adenocarcinoma: review and update Metastatic pancreatic cancer: Is there a light at the end of the tunnel?Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Therapeutic options for the management of pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.Pancreatic adenocarcinoma The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Systemic therapy for metastatic pancreatic adenocarcinoma.Inflammatory features of pancreatic cancer highlighted by monocytes/macrophages and CD4+ T cells with clinical impact.Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers Efficacy of systemic therapy in advanced pancreatic carcinoma.Clinical experiences with G17DT in gastrointestinal malignancies.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.Pancreatic cancer: a review of recent advances.

P2860

Q24240739-333F651B-E29F-45DA-9E3E-173643D88A21 Q24245085-C3732558-A311-456C-B87B-93EB1412077C Q24657439-7B02A460-6D87-4D44-AE0A-67BEB8CD8D40 Q26750440-430A70A3-988D-4BD2-80C5-9641595C40EA Q26830913-8348C934-110D-4F94-AF1F-8C74E0CFFACE Q28082919-B43DA502-EB0B-4876-8CCF-280CF101BE74 Q33370390-0331CD65-BD3C-4758-B85A-DCCEACB73510 Q33378968-6AC33CFA-2B13-4F9F-9F25-D128DDF06C30 Q33380084-2A39469C-364F-4323-A523-62B1CCAA8503 Q33394729-098CE876-80FF-4432-A0ED-37ED5F0DC186 Q33395047-70FF9D76-AC12-4F24-B5BA-C062B157BD90 Q33395577-898A35C8-1AF2-47B1-B882-05D96B25BE2F Q33412001-677FFBD6-3F9C-4E01-A41B-1B1BCB20D223 Q33428382-9006AEBB-679B-4C41-89AC-50BCE82D904B Q33440500-C83DD779-B661-4C00-9AF4-99EB1C7596D7 Q33621256-04C3F183-C824-439B-B848-1F41B7DEE44C Q33632330-F5D88785-625D-4085-A6A1-16B00C0AE068 Q33898080-8D3D822B-1E5B-483F-90B9-CAEF2FD2CF0C Q34093776-8C457D91-F8CC-4C0D-B05D-4F89B50DA507 Q34129346-AC66BA7D-D469-4156-B5E4-CFD26A256539 Q34137350-0A06555E-43C3-4BA1-99FD-26711D96B605 Q34140498-03C2C6F0-12F8-4CF0-8393-DD01A8EB81F0 Q34226670-221C6BD1-199A-4E55-99FF-864388E740FD Q34313870-E10F1E03-C485-4701-A95E-A8CD16DD6DF4 Q34363486-739BB46F-D87A-4EB5-AC43-483619FFF888 Q34422252-E270BA7D-F23E-463A-8F50-6710ED5592F0 Q34631279-D8E01783-AC3E-4ED1-9ECF-4619750FD0C4 Q34818494-53661D95-0530-4DD9-A524-3DF40987ACFD Q35076238-1E734A80-41B2-4DFB-862F-B042C9048109 Q35754232-FF4621E3-4580-4A1A-A9D8-A81604B9BF06 Q35781556-C1233486-9592-496D-825F-5948899152FE Q36035888-72B1A682-16DD-44C0-8B5B-910DB94357BC Q36072772-5C7BA19D-2A1B-4C1F-A08B-C040EA4D2877 Q36084097-B47843B4-6C4A-4F87-99BE-BA750CD26395 Q36384541-5D20C067-16C6-4FFC-826E-E612A8B911FD Q36425154-0D195D76-B5B4-446D-85DD-BF7CBB7D0D73 Q36448668-DFDFDBFE-50B8-4227-A8A9-FF67AC00747E Q36610441-9BE9EA7A-D145-4247-A1B9-0ECA8897B881 Q36614272-C2168B65-9CC8-4199-ADA3-E6EC72AA9170 Q36623071-B4F630BF-F48C-4A5E-A96C-09B935A8916F

P2860

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

http://www.wikidata.org/entity/Q33366562

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@ast

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@en

type

label

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@ast

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@en

prefLabel

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@ast

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@en

P1433

Q33366562-75BDB479-508A-4425-9BA0-6F5F09029BFA

P1476

Q33366562-3200BCB1-B48F-44CD-B9DF-7072CBBBE800

P2093

Q33366562-0770C849-AAF9-40D8-A5EB-F3238530438C

Q33366562-0CF98CE7-FD17-49E7-8FAD-2439BBD330AC

Q33366562-12A95C1C-02F9-479A-9EED-2F21B4A30E5A

Q33366562-1D2D558A-9EC7-413D-9D53-E53E1F3EE672

Q33366562-1E047BDC-2C88-4B16-829C-896EB5031AD8

Q33366562-23CCE2EB-DEE3-4F0B-8669-1003553E1D86

Q33366562-26970BD1-CDA6-4D9D-A1BA-B3D34A58C491

Q33366562-4123D2E5-06D1-44F2-8110-1BDDF37B8997

Q33366562-44FBCF46-ADB0-4800-A34D-174C7A8DBDC2

Q33366562-504E435F-1855-4E36-99AA-E0E3A7D87E4C

P304

Q33366562-32533AD6-5336-4E58-A758-F8DBD6B0FD8B

P31

Q33366562-74F3386D-94C5-44EF-851A-1A59C474ADDD

P356

Q33366562-4088A0A1-C87B-4BE0-88AA-CE8CC6CBE148

P433

Q33366562-A9965C57-196A-480B-B3AF-B02B38D6B211

P478

Q33366562-EB737064-068F-46BC-BCE7-637B02039B79

P50

Q33366562-DDECBD2D-E7A9-4EA4-A928-5C57ED315062

P577

Q33366562-2EF1C176-931D-4FDC-9926-751619D16540

P698

Q33366562-5AD6B5A6-B799-4000-B193-02B83D48BCFD

P921

Q33366562-9F33BC97-3791-4484-B1B7-0925967EE5C2

Q33366562-FD30DAED-9653-4917-8A76-9698E2320A6F

P356

S1470-2045(05)70175-3

P1433

The Lancet Oncology

P1476

Gemcitabine versus cisplatin, ...... d multicentre phase III trial.

@en

P2093

Alessandro Zerbi

http://www.w3.org/2001/XMLSchema#string

Carlo Milandri

http://www.w3.org/2001/XMLSchema#string

Carlo Staudacher

http://www.w3.org/2001/XMLSchema#string

Cristina Oliani

http://www.w3.org/2001/XMLSchema#string

Elisa Bonetto

http://www.w3.org/2001/XMLSchema#string

Eugenio Villa

http://www.w3.org/2001/XMLSchema#string

Gabriele Luppi

http://www.w3.org/2001/XMLSchema#string

Gianpaolo Balzano

http://www.w3.org/2001/XMLSchema#string

Laura Galli

http://www.w3.org/2001/XMLSchema#string

Luca Aldrighetti

http://www.w3.org/2001/XMLSchema#string

P304

369-376

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S1470-2045(05)70175-3

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Alessandro Passardi

P577

2005-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15925814

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

multicenter trial